Doctors have long relied on painful procedures to diagnose and monitor certain blood cancers. One of these cancers is multiple myeloma, a disease that starts in the bone marrow.
Bone marrow is the soft tissue inside bones where blood cells are made. In people with myeloma, abnormal cells grow in this area and produce harmful proteins that can damage the body.
To check for this cancer, doctors usually perform a bone marrow biopsy. This procedure involves inserting a thick needle deep into a bone to remove a small sample. The sample is then tested for cancer cells.
While this method can provide important information, it is uncomfortable, invasive, and sometimes risky. Many patients need to repeat this test regularly, even after treatment, to check if the cancer has returned.
This process can be especially difficult for older adults, who make up most people diagnosed with myeloma.
Many of them have weaker bones or limited movement, which increases the risks of the procedure.
Because of these challenges, scientists have been searching for a simpler and safer way to monitor this disease.
A research team at Rapid Novor, a company connected to the University of Waterloo, has developed a promising solution.
Their new test, called EasyM, uses a simple blood sample instead of a bone marrow biopsy. This idea may sound simple, but it is based on advanced science and years of research.
The key to this test is something called M-protein. This protein is produced by myeloma cells and can be found in the blood. Doctors have known about M-protein for many years, but it has been difficult to measure it accurately because many other proteins in the blood look similar.
To solve this problem, the researchers used a method called de novo sequencing. This method allows scientists to identify the exact structure of proteins by analyzing their building blocks. Each patient’s M-protein has a unique pattern, almost like a fingerprint. By identifying this pattern, the test can clearly separate the harmful protein from normal ones.
This makes the test much more sensitive than older methods. It can detect even very small amounts of M-protein in the blood. Because of this, doctors can track how the disease is changing over time and see if treatment is working.
One of the most important findings is that this test can detect cancer relapse earlier than current methods. In some cases, it can find signs of the disease returning months before a bone marrow biopsy would. This gives doctors more time to respond and adjust treatment.
Another advantage is that blood circulates throughout the entire body. This means the test gives a more complete picture of the disease. In contrast, a biopsy only checks one small area of bone. If the cancer is not in that exact spot, it may be missed.
The study behind this work was shared through research connected to the University of Waterloo and Rapid Novor. It shows how combining computer science with biology can lead to new medical tools that improve patient care.
Looking at these findings, the new test appears to offer clear benefits. It is less painful, easier to repeat, and may provide earlier and more accurate results. However, more research will still be needed to confirm its long-term reliability and to expand its use in different healthcare systems.
Overall, this study highlights a major step forward in cancer care. It shows how technology can reduce patient suffering while improving medical results. If widely adopted, this type of testing could change how doctors diagnose and monitor blood cancers in the future.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
